Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience

• Autoři: WEINBERGEROVÁ Barbora; ČERŇAN Martin; KABUT Tomáš; SEMERÁD Lukáš; PODSTAVKOVÁ Natália; SZOTKOWSKI Tomáš; JEŽÍŠKOVÁ Ivana; MAYER Jiří
• Rok publikování: 2023
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Haematologica
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://haematologica.org/article/view/haematol.2022.282263
• Doi: http://dx.doi.org/10.3324/haematol.2022.282263
• Klíčová slova: Gemtuzumab ozogamicin; midostaurin; acute myeloid leukemia

Přiložené soubory

• Gemtuzumab_ozogamicin_plus_midostaurin_in_conjunction_with_standard_intensive_therapy_for_FLT3-_mutated_acute_myeloid_leukemia_patients_-_Czech_Center_experience.pdf

• Popis: For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been represented by cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). In recent years, approach to the treatment of AML has significantly shifted toward the use of novel and effective, target-directed therapies, including anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin (MIDO).

Související projekty

• Národní ústav pro výzkum rakoviny